Medical AI Alliance
← Company Index
Pharma & CDMOKOSPI 185750635 approvals367 trials

Chong Kun Dang Pharmaceutical Corp.

Official website

Spun off and listed in 2013, Chong Kun Dang out-licensed its HDAC6 inhibitor CKD-510 to Novartis in a deal worth about KRW 1.7 trillion.

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Spun off in November 2013 and listed on the KOSPI the following month, Chong Kun Dang Pharmaceutical is a pharmaceutical company. Its portfolio includes Camtobell, Korea's 8th approved new drug and an anticancer agent (2004); Duvie, Korea's 20th approved new drug for diabetes (2013); Nespevel, the world's first Nesp biosimilar approved in Korea and Japan; Jitec, a botanical drug for gastritis approved domestically in 2022; Lucentis biosimilar Lucenbiez, approved domestically in 2022 and launched in 2023; and existing products such as Gliatilin and Dilatrend. The company invests about 9-11% of revenue in R&D and, in November 2023, signed a technology out-licensing deal worth about KRW 1.7 trillion with Novartis for research, clinical development, and commercialization rights to the HDAC6 inhibitor CKD-510.

Products & technology

  • CamtobellAnticancer agent (Korea's 8th approved new drug)
  • DuvieDiabetes treatment (Korea's 20th approved new drug)
  • NespevelNesp biosimilar
  • JitecGastritis treatment (botanical drug)
  • LucenbiezLucentis biosimilar
  • Gliatilinexisting product
  • Dilatrendexisting product

Regulatory approvals

data.go.kr

633 Korean MFDS drug approvals · 1960–2026 / 2 Korean MFDS device approvals · 2018–2019

  • MFDS drugBelldoxia Tab. 15mg2026-08-21
    Drug · Prescription · Approval202602433
  • MFDS drugBelldoxia Tab. 30mg2026-08-21
    Drug · Prescription · Approval202602434
  • MFDS drugBelldoxia Tab. 60mg2026-08-21
    Drug · Prescription · Approval202602435
  • MFDS drugVinobelin Injection2026-06-30
    Drug · Prescription · Approval202601860
  • MFDS drugBenfobell Alpha Tab.2026-06-17
    Drug · OTC · Notification202601715
  • MFDS drugPenzal 500 Powder2026-06-11
    Drug · OTC · Notification202601655
  • MFDS drugModcol Cold Strong Soft Cap.2026-05-12
    Drug · OTC · Notification202601383
  • MFDS drugModcol Nose Strong Soft Cap.2026-05-12
    Drug · OTC · Notification202601384
  • MFDS drugModcol Ibu Cough Soft Cap.2026-04-29
    Drug · OTC · Notification202601272
  • MFDS drugModcol Tea Night Effervescent Tab.2026-04-29
    Drug · OTC · Notification202601276
  • MFDS drugPenzal 500 Tab.2026-04-29
    Drug · OTC · Notification202601277
  • MFDS drugModcol Ibu Cold Soft Cap.2026-04-24
    Drug · OTC · Notification202601208
Show 68 more
  • MFDS drugGenbig Triple Speed Solution2026-04-23
    Drug · OTC · Notification202601185
  • MFDS drugModcol Cough Strong Soft Cap.2026-04-23
    Drug · OTC · Notification202601190
  • MFDS drugModcol Ibu Nose Soft Cap.2026-04-15
    Drug · OTC · Notification202601089
  • MFDS drugOlobella 0.7 SD Eye Drops2026-03-27
    Drug · Prescription · Approval202600865
  • MFDS drugEsoduo-mini Tab. 10/350mg2026-03-27
    Drug · Prescription · Approval202600876
  • MFDS drugGrabella 1.5% SD Ophthalmic solution2026-03-26
    Drug · Prescription · Approval202600847
  • MFDS drugNeuropesil Tab. 3mg2026-03-18
    Drug · Prescription · Approval202600786
  • MFDS drugDuviempol XR Tab. 0.25/12.5/1000mg2026-03-10
    Drug · Prescription · Approval202600714
  • MFDS drugDuviempol XR Tab. 0.5/10/1000mg2026-03-10
    Drug · Prescription · Approval202600715
  • MFDS drugDuviempol XR Tab. 0.5/25/1000mg2026-03-10
    Drug · Prescription · Approval202600716
  • MFDS drugOtinib tablet 40 mg (Osimertinib mesylate)2026-01-27
    Drug · Prescription · Approval202600226
  • MFDS drugOtinib tablet 80 mg (Osimertinib mesylate)2026-01-27
    Drug · Prescription · Approval202600227
  • MFDS drugDuviempa Tab. 0.5/25mg2025-12-19
    Drug · Prescription · Approval202503330
  • MFDS drugDuviempa Tab. 0.5/10mg2025-12-19
    Drug · Prescription · Approval202503331
  • MFDS drugTelminuvo Plus Tab. 80/2.5/25mg2025-10-31
    Drug · Prescription · Approval202502824
  • MFDS drugTelminuvo Plus Tab. 80/2.5/12.5mg2025-10-31
    Drug · Prescription · Approval202502825
  • MFDS drugTelminuvo Plus Tab. 40/2.5/12.5mg2025-10-31
    Drug · Prescription · Approval202502826
  • MFDS drugDermagram PDRN Cream2025-09-26
    Drug · OTC · Notification202502554
  • MFDS drugBriveta Tablet 50mg (brivaracetam)2025-09-23
    Drug · Prescription · Approval202502511
  • MFDS drugBriveta Tablet 10mg (brivaracetam)2025-09-23
    Drug · Prescription · Approval202502512
  • MFDS drugBriveta Tablet 25mg (brivaracetam)2025-09-23
    Drug · Prescription · Approval202502513
  • MFDS drugBriveta Tablet 100mg (brivaracetam)2025-09-23
    Drug · Prescription · Approval202502514
  • MFDS drugTelminuvo Tab. 20/1.25mg(Telmisartan, S-Amlodipine Besylate Dihydrate)2025-08-29
    Drug · Prescription · Approval202502268
  • MFDS drugKeyfobell powder2025-08-12
    Drug · OTC · Notification202502081
  • MFDS drugBenfobell I Soft Cap.2025-08-11
    Drug · OTC · Notification202502077
  • MFDS drugCenbido Injection2025-08-01
    Drug · Prescription · Approval202502017
  • MFDS drugWonder-V inj.2025-07-31
    Drug · Prescription · Approval202502008
  • MFDS drugCKD Topiramate XR tablet 25mg2025-07-25
    Drug · Prescription · Approval202501907
  • MFDS drugCKD Topiramate XR tablet 50mg2025-07-25
    Drug · Prescription · Approval202501908
  • MFDS drugEmpamax M XR tab. 10/1000mg2025-07-24
    Drug · Prescription · Approval202501898
  • MFDS drugEmpamax M XR tab. 25/1000mg2025-07-24
    Drug · Prescription · Approval202501899
  • MFDS drugEmpamax M XR tab. 12.5/750mg2025-07-24
    Drug · Prescription · Approval202501900
  • MFDS drugEmpamax M XR tab. 12.5/1000mg2025-07-24
    Drug · Prescription · Approval202501901
  • MFDS drugCKD Easyquick solution2025-07-18
    Drug · OTC · Notification202501826
  • MFDS drugDermagram Soft Cap.2025-07-08
    Drug · OTC · Notification202501707
  • MFDS drugZangTrahola Enteric Soft Capsule(Peppermint Oil)2025-06-25
    Drug · OTC · Approval202501572
  • MFDS drugKefem Gongpas Plaster2025-06-17
    Drug · OTC · Notification202501474
  • MFDS drugModcol Kidspen Syrup(Acetaminophen)2025-06-10
    Drug · OTC · Notification202501414
  • MFDS drugKEFEM Cool & Hot Plaster2025-05-22
    Drug · OTC · Notification202501274
  • MFDS drugPitalou F tab. 2/160mg2025-04-30
    Drug · Prescription · Approval202501048
  • MFDS drugIriquick tablet 2.5mcg2025-04-30
    Drug · Prescription · Approval202501061
  • MFDS drugIriquick tablet 5mcg2025-04-30
    Drug · Prescription · Approval202501066
  • MFDS drugADCAL Q Tab.2025-04-28
    Drug · OTC · Notification202501017
  • MFDS drugAdcal D Tab.2025-04-24
    Drug · OTC · Notification202500989
  • MFDS drugNeuromanthyn Tab. 20mg2025-04-21
    Drug · Prescription · Approval202500939
  • MFDS drugEmsiformin XR Tab. 12.5/50/750mg2025-04-16
    Drug · Prescription · Approval202500914
  • MFDS drugEmsiformin XR Tab. 25/100/1000mg2025-04-16
    Drug · Prescription · Approval202500915
  • MFDS drugEmsiformin XR Tab. 5/50/750mg2025-04-16
    Drug · Prescription · Approval202500916
  • MFDS drugEmsiformin XR Tab. 10/100/1000mg2025-04-16
    Drug · Prescription · Approval202500917
  • MFDS drugEmpamax S Tab. 25/100mg2025-04-07
    Drug · Prescription · Approval202500821
  • MFDS drugEmpamax S Tab. 10/100mg2025-04-07
    Drug · Prescription · Approval202500822
  • MFDS drugNUVOROZET tab. 80/2.5/10/10mg2025-03-21
    Drug · Prescription · Approval202500656
  • MFDS drugNUVOROZET tab. 80/2.5/5/10mg2025-03-21
    Drug · Prescription · Approval202500657
  • MFDS drugLipilouzet Tab. 10/5mg2024-12-27
    Drug · Prescription · Approval202403092
  • MFDS drugNeuropezilM Tab. 10/20mg2024-12-23
    Drug · Prescription · Approval202403049
  • MFDS drugGlowwings powderRevoked2024-10-21
    Drug · OTC · Notification202402467
  • MFDS drugDermagram Gel2024-10-14
    Drug · OTC · Notification202402425
  • MFDS drugEfinabell Topical Solution2024-07-08
    Drug · Prescription · Approval202401670
  • MFDS drugTelminuvo Tab. 20/2.5mg(Telmisartan, S-Amlodipine Besylate Dihydrate)2024-07-04
    Drug · Prescription · Approval202401637
  • MFDS drugCogniX Tab.2024-04-30
    Drug · OTC · Notification202401072
  • MFDS drugNexcholine Tab. 10mg2024-04-24
    Drug · Prescription · Approval202400967
  • MFDS drugOtebell Tab.2024-04-17
    Drug · Prescription · Approval202400869
  • MFDS drugLipilou Tab. 5mg2024-03-11
    Drug · Prescription · Approval202400512
  • MFDS drugNexcholine Tab. 30mg2024-02-26
    Drug · Prescription · Approval202400403
  • MFDS drugDermagram Solution2024-02-16
    Drug · OTC · Notification202400335
  • MFDS drugEyeresh eye drop (single use)2024-01-29
    Drug · OTC · Notification202400209
  • MFDS drugKEFEM Gel2024-01-11
    Drug · OTC · Notification202400086
  • MFDS drugANYDIPINE S TAB 1.25MG2023-08-01
    Drug · Prescription · Approval202302314

Showing the 80 most recent of 635 records.

Clinical trials

data.go.kr

367 MFDS clinical trial authorisations · 2012–2026 (Phase 1 185 · Bioequivalence 134 · Phase 3 36 · Phase 2 10 · Phase 1/2a 2)

  • Phase 3CKD-3392026-07-27

    29 trial sites

  • BioequivalenceCKD-2992026-07-24

    2 trial sites

  • BioequivalenceCKD-2292026-06-05

    2 trial sites

  • BioequivalenceCKD-2622026-04-30

    1 trial site

  • BioequivalenceCKD-2542026-03-10

    1 trial site

  • BioequivalenceCKD-2542026-03-10

    1 trial site

  • Phase 1/2aCKD-7032026-02-10

    5 trial sites

  • Phase 1CKD-3392026-01-30

    2 trial sites

  • BioequivalenceCKD-2992026-01-07

    2 trial sites

  • BioequivalenceCKD-2152025-11-26

    5 trial sites

  • Phase 1CKD-8462025-11-26

    2 trial sites

  • Phase 1CKD-3832025-09-23

    2 trial sites

Show 68 more
  • Phase 1CKD-3832025-09-23

    2 trial sites

  • Phase 1CKD-3832025-09-23

    2 trial sites

  • BioequivalenceCKD-2492025-07-29

    2 trial sites

  • Phase 3CKD-3562025-06-30
  • BioequivalenceCKD-2162025-06-10

    2 trial sites

  • BioequivalenceCKD-2382025-03-27

    2 trial sites

  • BioequivalenceCKD-228(7_1)2025-03-21

    1 trial site

  • BioequivalenceCKD-228(4_1)2025-03-21

    1 trial site

  • BioequivalenceCKD-2682025-03-19

    2 trial sites

  • BioequivalenceCKD-2682025-03-19

    2 trial sites

  • BioequivalenceCKD-2182025-03-17

    2 trial sites

  • BioequivalenceCKD-228(14_1)2025-03-17

    1 trial site

  • Phase 1CKD-5122025-03-12

    8 trial sites

  • BioequivalenceCKD-2062024-12-04

    2 trial sites

  • Phase 1CKD-3242024-11-01

    2 trial sites

  • Phase 1CKD-3832024-10-31

    2 trial sites

  • Phase 1CKD-3832024-10-31

    2 trial sites

  • Phase 1CKD-3792024-10-21

    2 trial sites

  • Phase 1CKD-3782024-10-17

    2 trial sites

  • BioequivalenceD4892024-10-09

    2 trial sites

  • BioequivalenceCKD-2182024-08-09

    2 trial sites

  • Phase 3CKD-8432024-07-24

    25 trial sites

  • Phase 1CKD-3832024-06-12

    2 trial sites

  • Phase 1CKD-3782024-05-02

    2 trial sites

  • BioequivalenceCKD-2102024-04-08

    2 trial sites

  • Phase 1CKD-3832024-03-06

    2 trial sites

  • Phase 1CKD-3412024-02-05

    2 trial sites

  • BioequivalenceCKD-2062024-01-17

    2 trial sites

  • Phase 3CKD-202A2023-12-15

    51 trial sites

  • Phase 1CKD-3482023-11-29

    2 trial sites

  • Phase 1CKD-3792023-09-27

    1 trial site

  • Phase 1CKD-8462023-09-21

    2 trial sites

  • BioequivalenceD9782023-08-11

    2 trial sites

  • BioequivalenceD9782023-08-10

    2 trial sites

  • Phase 1CKD-3912023-08-07

    2 trial sites

  • BioequivalenceKBP-5012023-06-16

    2 trial sites

  • Phase 3CKD-8282023-05-22

    11 trial sites

  • Phase 1CKD-3412023-05-22

    2 trial sites

  • Phase 1CKD-3832023-05-18

    2 trial sites

  • Phase 1CKD-3792023-05-15

    1 trial site

  • BioequivalenceCKD-2092023-05-15

    2 trial sites

  • Phase 1CKD-8282023-05-08
  • Phase 1CKD-3792023-04-26

    1 trial site

  • Phase 1CKD-3782023-04-24

    2 trial sites

  • Phase 1CKD-8282023-04-21
  • BioequivalenceCKD-2062023-04-20

    2 trial sites

  • Phase 1CKD-3782023-03-24

    2 trial sites

  • Phase 1CKD-3832023-03-24

    2 trial sites

  • Phase 1CKD-3482023-02-22

    2 trial sites

  • Phase 1CKD-3862023-02-14

    2 trial sites

  • Phase 3CKD-8282023-02-07

    17 trial sites

  • Phase 1CKD-3792023-01-20

    1 trial site

  • Phase 1CKD-3872022-12-29

    2 trial sites

  • Phase 1CKD-3912022-12-15

    2 trial sites

  • Phase 3CKD-3912022-11-08

    20 trial sites

  • Phase 2CKD-4982022-10-17

    16 trial sites

  • Phase 1CKD-3412022-09-29

    2 trial sites

  • Phase 1CKD-8432022-09-20

    2 trial sites

  • Phase 1CKD-3862022-09-15

    2 trial sites

  • Phase 1CKD-3482022-09-15

    2 trial sites

  • Phase 1CKD-3712022-09-06

    2 trial sites

  • Phase 1CKD-8282022-08-26
  • Phase 1CKD-3872022-07-26

    2 trial sites

  • Phase 1CKD-3872022-07-26

    2 trial sites

  • Phase 3CKD-8282022-07-26

    9 trial sites

  • Phase 3CKD-3712022-06-29

    26 trial sites

  • Phase 1CKD-3792022-05-31

    1 trial site

  • Phase 1CKD-3312022-04-18

    2 trial sites

Showing the 80 most recent of 367 records.

R&D and key agreements

Source: DART corporate disclosure

CKD-510 · HDAC6 저해제 · Signed a technology out-licensing agreement with Novartis in November 2023 for research, clinical development, and commercialization rights, valued at about KRW 1.7 trillion.

표적항암제·바이오신약 파이프라인 · 임상 진행중 · Conducting clinical trials for various new drug candidates including targeted anticancer agents and biologics.

Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

HUONS CO., LTD.1 shared

KOSDAQ-listed pharmaceutical and healthcare company producing lidocaine anesthetics and the Kynix hyaluronic-acid eye-drop line.

BIOBIJOU Co., Ltd.1 shared

KOSDAQ-listed aesthetics exporter behind HA skin booster CANDOLOV SERUM and filler brands COLENA and CANDORLOV.

L&C BIO Co., Ltd1 shared

L&C BIO manufactures human tissue grafts across 11 tissue types, including the acellular dermal matrix MegaDerm, plus tissue-based medical devices.

Hanmi Pharm. Co., Ltd.1 shared

KOSPI-listed pharmaceutical company behind the combination drugs Amosartan (hypertension) and Rosuzet (dyslipidemia).

DongBang Medical Co., Ltd.1 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

Daehan Nupharm Co.,Ltd.1 shared

KOSDAQ-listed pharmaceutical company producing a diverse, low-volume portfolio of metabolic disease drugs, wellness injections, and veterinary medicines.

HANS BIOMED CORPORATION1 shared

KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.

Medy-Tox Inc.1 shared

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

Hironic Co.,Ltd1 shared

KOSDAQ-listed medical device company producing HIFU devices DOUBLO/V-RO and the Synerjet non-invasive drug delivery system for aesthetic dermatology.

PharmaResearch Co., Ltd.1 shared

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

CELLUMED CO., LTD.1 shared

KOSDAQ-listed holding company making medical devices and biologics including bone graft rhBMP2 and knee implant TKR.

CAREGEN CO.,LTD.1 shared

CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.

Sources and updates

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
AI visibility
Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition